Codexis (CDXS) Competitors $2.54 +0.02 (+0.79%) Closing price 10/3/2025 04:00 PM EasternExtended Trading$2.51 -0.03 (-1.22%) As of 04:30 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock CDXS vs. ZBIO, GERN, MYGN, VSTM, RIGL, LXRX, EBS, XOMA, VNDA, and CBIOShould you be buying Codexis stock or one of its competitors? The main competitors of Codexis include Zenas BioPharma (ZBIO), Geron (GERN), Myriad Genetics (MYGN), Verastem (VSTM), Rigel Pharmaceuticals (RIGL), Lexicon Pharmaceuticals (LXRX), Emergent Biosolutions (EBS), XOMA Royalty (XOMA), Vanda Pharmaceuticals (VNDA), and Crescent Biopharma (CBIO). These companies are all part of the "biotechnology" industry. Codexis vs. Its Competitors Zenas BioPharma Geron Myriad Genetics Verastem Rigel Pharmaceuticals Lexicon Pharmaceuticals Emergent Biosolutions XOMA Royalty Vanda Pharmaceuticals Crescent Biopharma Zenas BioPharma (NASDAQ:ZBIO) and Codexis (NASDAQ:CDXS) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, analyst recommendations, profitability, earnings, risk, institutional ownership, dividends and valuation. Which has better valuation and earnings, ZBIO or CDXS? Codexis has higher revenue and earnings than Zenas BioPharma. Zenas BioPharma is trading at a lower price-to-earnings ratio than Codexis, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioZenas BioPharma$5M183.26-$156.99M-$3.55-6.13Codexis$59.35M3.86-$65.28M-$0.83-3.06 Does the media refer more to ZBIO or CDXS? In the previous week, Zenas BioPharma had 4 more articles in the media than Codexis. MarketBeat recorded 4 mentions for Zenas BioPharma and 0 mentions for Codexis. Codexis' average media sentiment score of 1.83 beat Zenas BioPharma's score of 0.76 indicating that Codexis is being referred to more favorably in the news media. Company Overall Sentiment Zenas BioPharma Positive Codexis Very Positive Is ZBIO or CDXS more profitable? Zenas BioPharma has a net margin of 0.00% compared to Codexis' net margin of -113.67%. Zenas BioPharma's return on equity of -59.21% beat Codexis' return on equity.Company Net Margins Return on Equity Return on Assets Zenas BioPharmaN/A -59.21% -50.56% Codexis -113.67%-105.83%-46.06% Do insiders & institutionals believe in ZBIO or CDXS? 78.5% of Codexis shares are held by institutional investors. 16.5% of Zenas BioPharma shares are held by insiders. Comparatively, 1.9% of Codexis shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Do analysts rate ZBIO or CDXS? Zenas BioPharma currently has a consensus price target of $36.67, indicating a potential upside of 68.50%. Codexis has a consensus price target of $11.00, indicating a potential upside of 333.07%. Given Codexis' higher possible upside, analysts clearly believe Codexis is more favorable than Zenas BioPharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Zenas BioPharma 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50Codexis 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 SummaryCodexis beats Zenas BioPharma on 8 of the 15 factors compared between the two stocks. Get Codexis News Delivered to You Automatically Sign up to receive the latest news and ratings for CDXS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CDXS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CDXS vs. The Competition Export to ExcelMetricCodexisMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$229.29M$3.35B$6.11B$10.54BDividend YieldN/A2.28%5.66%4.69%P/E Ratio-3.0622.2887.1026.71Price / Sales3.86265.39538.92204.35Price / CashN/A46.3226.3031.09Price / Book3.109.9012.696.57Net Income-$65.28M-$52.45M$3.30B$276.78M7 Day Performance3.25%5.05%3.53%1.96%1 Month Performance4.96%10.61%6.74%9.11%1 Year Performance-19.62%25.03%72.67%31.60% Codexis Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CDXSCodexis3.2967 of 5 stars$2.54+0.8%$11.00+333.1%-19.6%$229.29M$59.35M-3.06250Positive NewsZBIOZenas BioPharma1.6212 of 5 stars$20.57+2.4%$36.67+78.3%N/A$846M$5M-5.79N/AGERNGeron2.9256 of 5 stars$1.31+1.6%$3.79+189.0%-68.8%$823.04M$76.99M-10.0870MYGNMyriad Genetics3.7434 of 5 stars$7.24-6.0%$12.45+72.0%-69.6%$716.45M$832.90M-1.692,700VSTMVerastem2.4943 of 5 stars$8.64-2.8%$13.29+53.8%+203.1%$547.14M$2.14M-2.6350RIGLRigel Pharmaceuticals3.6542 of 5 stars$28.75+0.4%$38.20+32.9%+77.9%$513.55M$179.28M5.31160LXRXLexicon Pharmaceuticals3.0125 of 5 stars$1.39-0.7%$3.23+132.0%-16.6%$508.76M$58.43M-4.21140Positive NewsAnalyst UpgradeEBSEmergent Biosolutions4.3795 of 5 stars$8.93+0.2%$13.50+51.3%-2.5%$475.36M$812.50M3.642,420Positive NewsXOMAXOMA Royalty4.1893 of 5 stars$37.20+1.4%$69.50+86.8%+43.7%$443.39M$12.77M-24.0010VNDAVanda Pharmaceuticals4.2839 of 5 stars$4.91-3.7%$16.50+236.0%+17.3%$301.35M$203.47M-4.35290CBIOCrescent Biopharma4.4053 of 5 stars$12.29-1.1%$25.60+108.3%N/A$243M$10K-0.3550Short Interest ↑ Related Companies and Tools Related Companies ZBIO Alternatives GERN Alternatives MYGN Alternatives VSTM Alternatives RIGL Alternatives LXRX Alternatives EBS Alternatives XOMA Alternatives VNDA Alternatives CBIO Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CDXS) was last updated on 10/6/2025 by MarketBeat.com Staff From Our PartnersForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredU.S. Government Sparking Crypto RallyAltcoin ETFs could surge prices (do this now) My "Crypto Bull Run Millionaire Blueprint" breaks down exactl...Crypto 101 Media | SponsoredAnother gold high? Here’s the move Wall Street is missing …Gold has surged past $3,600 an ounce, up 45% in the last year, but Weiss Ratings analyst Sean Brodrick says th...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredElon’s Out 🚫. Trump’s DOGE Payouts Keep Flowing (Up to $32K a Year)DOGE payouts are already moving. Every 90 days, billions flow out — whether you’ve claimed your share or not. ...Angel Publishing | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Codexis, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Codexis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
